11. Anti-sars-cov-2 antibody levels and side effects in the elderly after Covid-19 vaccination in Hanoi and Hung Yen in 2021 - 2022
Main Article Content
Abstract
The purpose of this study was to report the anti-SARS-CoV-2 antibody levels after COVID-19 vaccination and side effects in elderly people in Hanoi and Hung Yen in 2021 - 2022. Results of a longitudinal follow-up study of 2 groups of subjects who received 2 doses of AstraZeneca vaccine and 2 doses of Pfizer vaccine followed by a 3rd dose of the Moderna vaccine, are as follows: in both groups, after the second injection, the concentration of anti-SARS-CoV-2 antibodies peaked at 14 days (14.8 U/ml for AstraZeneca and 118.2 U/ml for Pfizer) and gradually decreased to very low level at 3 months post-vaccination. However, antibody levels were higher in the Pfizer vaccine group than in the AstraZeneca vaccine group with concentrations of 5.1 U/ml and 9.9 U/ml, respectively. After the 3rd dose with Moderna, antibody levels spiked and remained high after 3 months in both groups (60.2 U/ml and 86.1 U/ml). Side effects after the first injection in the AstraZeneca group were higher than in the Pfizer group with symptoms of fever, fatigue, injection site manifestations, and increased pain sensation. However, the rate of these symptoms decreased sharply and there was no difference between the 2 groups after the 2nd injection. Conclusion: COVID-19 vaccines produce antibodies against the SARS-CoV-2 virus; however, the amount of this antibody varies between subjects and types of vaccine and changes over time after vaccination. The Astrazeneca group had a high rate of side effects after the 1st dose, but after the 2nd dose, the rate of these reactions decreased significantly and was similar to the Pfizer group.
Article Details
Keywords
Antibody concentration, SARS-CoV-2, AstraZeneca, Pfizer, Morderna, side effects vaccination
References
2. Chang JH, Chiou JF, Hung CS, et al. Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. Vaccines. 2022; 10(2): 312. doi:10.3390/vaccines10020312.
3. Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). The Lancet. 2021; 398(10304): 981-990. doi:10.1016/S0140-6736(21)01699-8.
4. Barin B, Kasap U, Selçuk F, Volkan E, Uluçkan Ö. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe. 2022; 3(4): e274-e283. doi:10.1016/S2666-5247(21)00305-0.
5. Wheeler SE, Shurin GV, Yost M, et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr. 9(1): e00341-21. doi:10.1128/Spectrum.00341-21.
6. Franco Mastroianni et al. SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up. https://doi.org/10.1016/j.jvacx.2022.100175.
7. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249): 467-478. doi:10.1016/S0140-6736(20)31604-4.
8. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | NEJM. Accessed November 2, 2021. https://www.nejm.org/doi/full/10.1056/nejmoa2035389.
9. Jeong S, Lee N, Lee SK, et al. Comparing Five SARS-CoV-2 Antibody Assay Results Before and After the First and Second ChAdOx1 nCoV-19 Vaccination Among Health Care Workers: A Prospective Multicenter Study. Journal of Clinical Microbiology. 0(ja): JCM.01788-21. doi:10.1128/JCM.01788-21.
10. Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. Published online October 14, 2020: NEJMoa2027906. doi:10.1056/NEJMoa2027906.
11. Nguyễn Thanh Hồi. Bước đầu mô tả nồng độ kháng thể kháng vi rút sau tiêm vắc-xin phòng COVID-19. https://tapchiyhocvietnam.vn/index.php/vmj/article/view/1219/1070.
12. Wei J, Pouwels KB, Stoesser N, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. Published online February 14, 2022: 1-11. doi:10.1038/s41591-022-01721-6.
13. “https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine adversereactions/coronavirus-vaccine-summary-ofyellow-card-reporting,” 2022.
14. Cristina Menni, Kerstin Klaser, Anna May. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study, The Lancet, 2021.